Patents by Inventor Antonio Ricci
Antonio Ricci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220135571Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 21, 2021Publication date: May 5, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Cosimo Dolente, Annick Goergler, Georg Jaeschke, Bernd Kuhn, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner, David Hewings, Yvonne Alice Nagel
-
Publication number: 20220127275Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.Type: ApplicationFiled: January 4, 2022Publication date: April 28, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA
-
Publication number: 20220112199Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.Type: ApplicationFiled: December 21, 2021Publication date: April 14, 2022Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Roger David Norcross, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20220041680Abstract: The present invention provides a process for the manufacture of GLP-1 analogues with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a C-terminal pseudoproline fragment A with a fragment B bound to a solid support, followed by deprotection and cleavage from the support and final purification to yield the desired peptide. The invention further provides intermediates useful in the manufacturing process.Type: ApplicationFiled: October 9, 2019Publication date: February 10, 2022Applicant: FRESENIUS KABI IPSUM S.R.L.Inventors: Giuseppina Maria INCISIVO, Andrea ORLANDIN, Antonio RICCI, Ivan GURYANOV, Walter CABRI
-
Patent number: 11242349Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.Type: GrantFiled: May 1, 2020Date of Patent: February 8, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Fionn O'Hara
-
Publication number: 20220033443Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.Type: ApplicationFiled: October 15, 2021Publication date: February 3, 2022Applicant: Fresenius Kabi iPSUM S.r.lInventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI
-
Patent number: 11168114Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.Type: GrantFiled: December 19, 2016Date of Patent: November 9, 2021Assignee: FRESENIUS KABI IPSUM S.R.LInventors: Antonio Ricci, Jacopo Zanon, Walter Cabri, Ivan Guryanov, Andrea Orlandin, Barbara Biondi, Fernando Formaggio, Dario Visentini
-
Publication number: 20210300844Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).Type: ApplicationFiled: June 3, 2021Publication date: September 30, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Georg Jaeschke, Lothar Lindemann, Antonio Ricci, Eric Vieira
-
Patent number: 11117890Abstract: The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 2, 2019Date of Patent: September 14, 2021Assignee: Hoffman La-Roche Inc.Inventors: Georg Jaeschke, Antonio Ricci, Daniel Rueher, Sandra Steiner, Martin Duplessis, Yvonne Alice Nagel, Bernd Kuhn
-
Publication number: 20210269452Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.Type: ApplicationFiled: May 9, 2021Publication date: September 2, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
-
Publication number: 20210238230Abstract: The present invention provides a process for the manufacture of peptidomimetic drug icatibant with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a protected C-terminal fragment bound to a solid support and a protected N-terminal fragment, followed by cleavage from the support and resulting in a crude peptide of high purity, which is further purified to obtain pure icatibant in high yield. The invention further provides intermediates useful in the manufacturing process.Type: ApplicationFiled: April 18, 2019Publication date: August 5, 2021Applicant: FRESENIUS KABI IPSUM S.R.L.Inventors: Walter CABRI, Alice POZZEBON, Angelo VIOLA, Antonio RICCI, Andrea BORGOGNO, Ivan GURYANOV
-
Patent number: 11059766Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof. Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).Type: GrantFiled: December 1, 2017Date of Patent: July 13, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Georg Jaeschke, Lothar Lindemann, Antonio Ricci, Eric Vieira
-
Patent number: 11034699Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.Type: GrantFiled: December 14, 2018Date of Patent: June 15, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
-
Publication number: 20210079005Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: November 25, 2020Publication date: March 18, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20210070739Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: ApplicationFiled: November 24, 2020Publication date: March 11, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Patent number: 10882848Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.Type: GrantFiled: June 21, 2019Date of Patent: January 5, 2021Assignee: Hoffmann-La Roche, Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20200399339Abstract: The present invention provides an improved process for the preparation of high purity glucagon comprising the use of Xmb-protected amino acids, wherein may Xmb include, e.g., 2,4,6-trimethoxybenzyl, 2,4-dimethoxybenzyl, or 2-hydroxy-4-methoxybenzyl. The process also comprises the use of building blocks such as pseudoprolines to avoid aggregation and obtain the product in high yield and purity.Type: ApplicationFiled: June 18, 2020Publication date: December 24, 2020Applicant: FRESENIUS KABI IPSUM S.R.L.Inventors: Andrea ORLANDIN, Antonio RICCI, Walter CABRI, Steve MCINTYRE, Alex SAUNDERS
-
Publication number: 20200361930Abstract: The present invention provides compounds that cause specifically the degradation of EGFR via the targeted ubiquitination of EGFR protein and subsequent proteasomal degradation. The present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: August 4, 2020Publication date: November 19, 2020Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
-
Publication number: 20200308171Abstract: Present invention provides bifunctional compounds that comprise an E3 Ubiquitin Ligase moiety that is linked to a moiety that inhibit EGFR, where the target protein can be proximate to the ubiquitin ligase to effect degradation of said protein. Present compounds are useful for the treatment of various cancers.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Applicants: Hoffmann-La Roche Inc., C4 Therapeutics, Inc.Inventors: Georg Jaeschke, Bernd Kuhn, Antonio Ricci, Daniel Rueher, Sandra Steiner, Yvonne Alice Nagel, Martin Duplessis, Kiel Lazarski, Yanke Liang
-
Publication number: 20200255440Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.Type: ApplicationFiled: May 1, 2020Publication date: August 13, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA